Ovarian Cancer: Page 2

Healthy Nevada Project: Community genetic testing needed
The study, conducted by researchers from the Healthy Nevada Project, focused on identifying carriers of hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia.
July 28, 2020
2020 07 28 17 56 2985 2020 07 27 Community Screening 400
Week in Review: Flurry of FDA actions | Google Health's pathology AI demo | Tool for typing serous ovarian cancer
Dear LabPulse Member,
June 18, 2020
Molecular genotyping shines light on serous ovarian cancer
High-grade serous ovarian cancer is the most malignant form of ovarian cancer, causing up to 70% of ovarian cancer deaths. The new study validated a new classifier tool called the predictor of high-grade serous ovarian carcinoma (HGSOC) molecular subtype (ProType), which encompasses 55 genes plus five housekeeping genes and is based on the NanoString platform.
June 17, 2020
2020 06 17 23 55 4085 Double Helix Strange Cancer Cell 400
At-home testing for genetic risk works for breast, ovarian cancers
The findings were presented at the American Society of Clinical Oncology (ASCO) meeting, which was held May 29 to 31 in a virtual format.
May 31, 2020
2019 12 03 21 13 6201 Home Magnifying Glass 400
FDA clears Myriad's ovarian cancer test
The clearance allows clinicians to use the test in women who are eligible for treatment with olaparib (Lynparza, Merck/AstraZeneca) in combination with bevacizumab (Avastin, Roche), the company said. Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor developed by AstraZeneca and Merck; Myriad has been collaborating with AstraZeneca since 2007 to develop companion diagnostics for Lynparza, according to the firm.
May 10, 2020
2019 11 04 21 37 0904 Ovarian Cancer 400
CMS broadens coverage for NGS tests in breast, ovarian cancers
In a decision memo issued January 27, CMS announced that it will be covering NGS tests that are cleared or approved by the U.S. Food and Drug Administration (FDA) for some patients. The agency explained that its coverage determination applies to patients who have breast or ovarian cancer, as long as the patient has a risk factor or clinical indication for germline (inherited) breast or ovarian cancer and has not been previously tested with the same test for the same germline genetic content.
January 26, 2020
2019 08 05 19 10 8249 Dollar Sign 400
Todos gains U.S. lab, Videssa cancer tests via Provista deal
Provista has developed a line of protein-based blood tests for the early diagnosis of cancer. Its Videssa Breast blood test is commercially available for help in interpreting abnormal or difficult-to-interpret imaging findings. Tests based on the same technology are being developed for endometrial cancer, ovarian cancer, and cancers associated with HPV.
January 8, 2020
2020 01 09 22 46 7361 Business Deal Corporate 400
NCCN updates pathology guidance in ovarian cancer
In the new version, released on November 26, the guidelines now read:
December 1, 2019
2019 12 02 21 08 0302 Uterus Pelvic 400
CA-125 blood test better than expected in ovarian cancer
In the study of 50,780 women with symptoms of ovarian cancer such as bloating and abdominal pain, 6.8% had an abnormally high level of CA-125 -- defined as at least 35 U/mL. Of those with high levels, it turned out that 10% had ovarian cancer, the researchers shared in a poster presentation.
November 4, 2019
2019 11 04 21 37 0904 Ovarian Cancer 400
CMS plans broader coverage for NGS in breast, ovarian cancer
The agency's review and terms and conditions on the matter were published on October 29 in a proposed national coverage determination (NCD). The agency advised coverage for next-generation sequencing with physician-ordered companion diagnostic tests approved or cleared by the U.S. Food and Drug Administration (FDA) and performed in a CLIA-certified lab. Patients must meet a range of conditions, according to CMS. They must have ovarian or breast cancer, have clinical indications for testing for hereditary cancer, and have never received a prior NGS test. Results will be provided to the treating physician.
October 29, 2019
2019 10 30 21 49 9027 Cms Building 400
Myriad's myChoice PARP companion test clears FDA
PARP inhibitors have become well-established in various lines of treatment for ovarian cancer. The latest approval for Zejula covers use in patients with advanced ovarian cancer after three or more prior chemotherapy regimens and who also test positive for homologous recombination deficiency (HRD). HRD is defined in one of two ways: by genomic instability with disease progression more than six months after a response to platinum-based chemotherapy treatment, or by a BRCA mutation that is deleterious or suspected to be deleterious. Zejula is the only PARP inhibitor with this particular indication in late-line ovarian cancer.
October 23, 2019
2019 07 02 18 56 7204 Ovarian Cancer 2 400
Genetic testing of all breast cancer patients may pay off
Currently, most guidelines advise genetic testing only for patients who meet certain criteria: for example, if someone in their family has tested positive for BRCA1/2 mutations, which cause the most concern in breast cancer as well as ovarian cancer. There are also issues associated with expanding testing, including costs.
October 6, 2019
2019 04 15 22 17 2307 Breast Cancer 400
Previous Page
Page 2 of 3
Next Page